Quick Answer
Keros Therapeutics, Inc. reported Net Income Loss of $87.01 million for the year ending 2025.
- Keros Therapeutics, Inc. showed an increase of +146.4% in Net Income Loss from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$3.18 million | Q2 2019: -$2.85 million | Q3 2019: -$3.55 million | Q1 2020: -$11.89 million | Q2 2020: -$10.76 million | Q3 2020: -$12.04 million | Q1 2021: -$15.89 million | Q2 2021: -$15.62 million | Q3 2021: -$20.30 million | Q1 2022: -$24.19 million | Q2 2022: -$27.27 million | Q3 2022: -$23.51 million | Q1 2023: -$35.80 million | Q2 2023: -$37.51 million | Q3 2023: -$39.44 million | Q1 2024: -$43.11 million | Q2 2024: -$45.26 million | Q3 2024: -$52.96 million | Q1 2025: $148.45 million | Q2 2025: -$30.70 million | Q3 2025: -$7.28 million.
- Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Net Income Loss has grown by 805.4%.
- Historical annual values: Fiscal year 2025: $87.01 million | Fiscal year 2024: -$187.35 million | Fiscal year 2023: -$152.99 million | Fiscal year 2022: -$104.68 million | Fiscal year 2021: -$58.74 million | Fiscal year 2020: -$45.36 million | Fiscal year 2019: -$12.34 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: